IRadimed Corporation (IRMD) Comparison with companies in other sectors?

IRadimed Corporation has a share price of 12.72M. You can analyze IRadimed Corporation (IRMD) competitors across different market sectors through stock heatmaps.

What are IRMD's NET and operating margins?

IRadimed Corporation (IRMD) operating margin is around 0.30, and net profit margin is approximately 0.26 as of the latest reports.

In what way does IRMD's earnings per share (EPS) trend reflect its financial momentum?

IRadimed Corporation (IRMD) EPS is 1.55 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for IRadimed Corporation is 36.34, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for IRadimed Corporation?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for IRadimed Corporation like P/E which is 36.08, P/B which is 7.93, and PEG which is 13.80. Compare them with sector averages to evaluate if the stock is priced fairly.

IRadimed Corporation

IRMD•NASDAQ

Healthcare

Medical - Devices

$56.32

$-0.28(-0.49%)

Fundamental Analysis of IRadimed Corporation (IRMD)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$1.55

P/E Ratio

36.34

ROE

0.23%

Net Margin

0.26%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$716.11M

Shares OutstandingTotal number of shares issued

$12.72M

Book Value/ShareNet worth per share

$7.08

Revenue/ShareAnnual revenue per share

$5.91

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$1.55

Net MarginNet income as percentage of revenue

26.33%

Operating MarginOperating income as percentage of revenue

30.13%

ROEReturn on shareholders' equity

23.28%

ROAReturn on total assets

19.45%

ROCEReturn on capital employed

24.29%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$1.10

Cash/ShareCash and equivalents per share

$3.96

FCF YieldFree cash flow as percentage of market cap

1.96%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

$0.64

Dividend YieldAnnual dividend as percentage of stock price

1.14%

Financial Ratios Analysis data is not available for IRMDFinancial Ratios Analysis details for IRMD are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for IRMDSector Benchmarking details for IRMD are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for IRadimed Corporation Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of IRadimed Corporation. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account IRadimed Corporation's unique business strengths and challenges.

Key Financial Metrics for IRadimed Corporation

For IRadimed Corporation, essential financial indicators include EPS 1.55, PE 36.34, and ROE 0.23. These key ratios reveal insights into IRadimed Corporation's profitability, valuation, and operational health. Understanding these metrics enables you to compare IRadimed Corporation with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of IRadimed Corporation

Metrics like Net Margin 26.33% and ROA 19.45% shed light on how well IRadimed Corporation is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether IRadimed Corporation can sustain its operations and continue growing in the future.

Valuation and Market Position of IRadimed Corporation

Using ratios such as P/B Ratio 7.93 and PEG Ratio 13.80, investors can assess whether IRadimed Corporation is appropriately valued based on its financials and growth potential. These figures, combined with IRadimed Corporation's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for IRadimed Corporation

Financial health indicators, such as Debt/Equity Ratio 0.001 and Cash Flow $1.10, provide a snapshot of IRadimed Corporation's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like IRadimed Corporation, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for IRadimed Corporation

Investing in IRadimed Corporation based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at IRadimed Corporation focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;